ラメラ魚鱗癬治療の世界市場-2023年～2030年

概要

ラメラ魚鱗癬は、コロジオンベビー、コロジオンベビー症候群または先天性ラメラ魚鱗癬とも呼ばれます。出生時に発現するまれな遺伝性皮膚疾患で、主に皮膚の発赤と広範な鱗屑を特徴とします。常染色体劣性先天性魚鱗癬（ARCI）と呼ばれる3つの遺伝性皮膚疾患の1つです。この皮膚疾患はいくつかの遺伝子の有害な変化によって引き起こされます。この疾患に関する最も一般的な遺伝子はTGM1です。その他の遺伝子としては、NIPAL4、ALOX12BおよびCYP4F22があります。

さらに、ラメラ魚鱗癬は生命を脅かすものではないが、重度の皮膚醜状を引き起こし、証明された治療法はないです。治療の主な目的は、過剰な経表皮水分喪失とそれに続く感染を止めることです。通常、ペトロラタムやラノリンを含む保湿クリーム、エモリエント剤、角質溶解（鱗屑防止）クリームなどを用いて局所的に治療します。抗生物質やレチノイド（合成ビタミンA誘導体薬）も治療に用いられます。

市場力学：促進要因

外用薬の採用増加

外用薬の採用増加と新規かつ先進的な外用薬の市場開拓が、予測期間中の市場を牽引するとみられます。保湿クリームなどの外用薬は、皮膚の厚い鱗屑や皮膚の乾燥など、ラメラ魚鱗癬の目に見える症状を管理するために極めて重要です。局所的な緩和をもたらすその能力は、採用増加の一因となっています。多くの製薬会社が新規外用剤の開発に注力しています。

例えば、2022年4月28日、ティンバー・ファーマシューティカルズInc、は、米国食品医薬品局（FDA）より、X連鎖性劣性魚鱗癬（XRI）および常染色体劣性先天性魚鱗癬であるラメラ魚鱗癬の治療薬として、同社が特許を有するIPEGデリバリーシステムを用いて製剤化されたイソトレチノイン外用剤TMB-001のファストトラック指定を受けたことを明らかにしました。

さらに、扁平上皮魚鱗癬の有病率の増加により、患者の予後を改善するための外用剤の需要が増加しています。例えば、米国国立衛生研究所（NIH）によると、ラメラ魚鱗癬はまれな遺伝性皮膚疾患であり、すべての集団が罹患し、有病率は30万人に1人未満です。

さらに、経口または注射で服用する全身薬とは異なり、局所薬は全身的な副作用のリスクを減らすことで、より局所的な効果を発揮します。このため、ラメラ魚鱗癬の治療において長期的に使用する場合には、外用薬が望ましい選択となります。外用薬は塗布が容易であることが知られており、治療のアドヒアランスを高めることで患者にとってより便利です。このため、ラメラ魚鱗癬の治療に外用薬の採用が増加しています。

さらに、ラメラ魚鱗癬の有病率の増加、臨床試験の増加、認知度の向上、個別化された治療オプションに対する需要の増加、新規薬剤や局所療法の開拓の進展は、予測期間にわたって市場を牽引すると予想される要因です。

阻害要因

外用クリームやその他の薬剤に関連する合併症や副作用、治療費の高さ、代替治療オプションの利用可能性、ラメラ魚鱗癬治療のためのより良い治療法の欠如などの要因が、市場の阻害要因になると予想されます。

このレポートの詳細情報- サンプル請求

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 外用薬の採用増加
  • 抑制要因
    • クリームに伴う副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• パイプライン分析
• アンメットニーズ分析
• 数量分析
• DMI意見

第6章 COVID-19分析

第7章 治療タイプ別

• 保湿クリーム
  • ペトロラタムクリーム
  • ラノリンクリーム
• エモリエント剤
• 角質溶解（スケーリング防止）クリーム
• 抗生物質
• レチノイド（合成ビタミンA誘導体医薬品）
• 保湿目薬
• その他

第8章 投与経路別

• 外用薬
• 経口剤
• その他

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• LGM Pharma
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Mylan Inc.
• Sebapharma GmbH & Co. KG
• Timber Pharmaceuticals LLC
• Galderma SA
• Beiersdorf AG
• DFB Technology, Ltd.
• Unilever PLC
• LANOLIPS PTY LTD
• Lanolin Beauty International

第13章 付録

Overview

Lamellar ichthyosis is also known as collodion baby, collodion baby syndrome, or congenital lamellar ichthyosis. It is a rare genetic skin disorder that is present at birth, mainly characterized by cutaneous redness and extensive scaling. It is one of three genetic skin disorders called autosomal recessive congenital ichthyoses (ARCI). This skin disorder is caused by harmful changes in several genes. The most common gene related to this condition is TGM1. Other genes include NIPAL4, ALOX12B, and CYP4F22.

Moreover, lamellar ichthyosis is not life-threatening but causes severe skin disfigurement and there is no proven cure. The main goal of treatment, which mostly addresses symptoms, is to stop excessive transepidermal water loss and subsequent infections. It is usually treated topically by using moisturizing creams containing petrolatum or lanolin, emollients, keratolytic (anti-scaling) creams and others. Antibiotics and retinoids (synthetic vitamin A derivative drugs) are also used in treatment.

Market Dynamics: Drivers

Increasing adoption of topical medications

The increasing adoption of topical medicines and the development of novel and advanced topical medications are expected to drive the market over the forecast period. Topical medicines such as moisturizing creams and others are crucial for managing the visible symptoms of lamellar ichthyosis, such as thick scales on the skin and dry skin. Their ability to provide localized relief contributes to their increased adoption. Many pharmaceutical companies are focussing on the development of novel topical agents.

For instance, on April 28, 2022, Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, cleared that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to TMB-001, a topical isotretinoin formulated using the company's patented IPEG delivery system, for the treatment of X-linked recessive ichthyosis (XRI) and autosomal recessive congenital ichthyosis, lamellar ichthyosis.

Moreover, the increasing prevalence of lamellar ichthyosis is increasing the demand for the topical agents for the better patient outcomes. For instance, according to the National Institute of Health (NIH), lamellar ichthyosis, a rare genetic skin disorder affects all populations, and the prevalence is less than 1 case per 300,000 individuals.

In addition, unlike systemic medications taken orally or by injection, topical medicines have a more localized effect by reducing the risk of systemic side effects. This makes them a preferred choice for long-term use in the treatment of lamellar ichthyosis. Topical medications are known for easier to apply and are more convenient for patients by enhancing treatment adherence. This increases the adoption of topical medications for the treatment of lamellar ichthyosis.

Further, the increasing prevalence of lamellar ichthyosis, increasing clinical trials, increasing awareness, increasing demand for personalized treatment options and advancements in the development of novel drugs and topical therapies are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and adverse effects associated with topical creams and other drugs, the high cost of the treatment, the availability of alternative treatment options and lack of better treatment for the treatment of lamellar ichthyosis are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global lamellar ichthyosis treatment market is segmented based on treatment type, route of administration, distribution channel and region.

The moisturizing creams segment accounted for approximately 53.2% of the lamellar ichthyosis treatment market share

The moisturizing creams segment is expected to hold the largest market share over the forecast period. Usually, there is no cure for lamellar ichthyosis, but moisturizing creams are considered first-line treatment for the management of the symptoms. The primary goal of using moisturizing creams is to provide symptomatic relief. By keeping the skin adequately moisturized, these creams help reduce itching, flaking, and discomfort associated with lamellar ichthyosis.

Moreover, dry and scaly skin in lamellar ichthyosis can lead to cracks and fissures. Moisturizing creams are known to create a protective layer on the skin, preventing these fissures from forming and minimizing the risk of infection. Regular use of moisturizing creams contributes to an improvement in skin texture. The scales may become less prominent, and the skin may feel smoother, enhancing the overall appearance.

Many moisturizing creams used for lamellar ichthyosis are available over the counter, making them easily accessible to patients without the need for a prescription. This accessibility contributes to their widespread use. In addition, their wide adoption also increases the demand for moisturizing creams.

Geographical Analysis

North America accounted for approximately 38.4% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the increasing research activities and advanced healthcare facilities. North America especially in the United States, boasts advanced healthcare infrastructure, including state-of-the-art medical facilities, specialized clinics, and well-established healthcare facilities. These facilities support the treatment and management of lamellar ichthyosis. Advanced healthcare infrastructure enhances accessibility to advanced therapies and contributes to the overall market growth.

The increasing prevalence in the region is expected to increase the demand for the market. For instance, according to the National Institutes of Health, lamellar ichthyosis is estimated to affect 1 in 100,000 individuals in the United States.

Furthermore, the United States is home to numerous research institutions, pharmaceutical companies, and academic centers. The region's robust research activities contribute to advancements in understanding lamellar ichthyosis and developing novel treatment options for better patient outcomes. Ongoing research fosters innovation and the discovery of new therapies, which can positively impact the market in the region.

Competitive Landscape

The major global players in the lamellar ichthyosis treatment market include: LGM Pharma, Mylan Inc., Sebapharma GmbH & Co. KG, Timber Pharmaceuticals LLC, Galderma SA, Beiersdorf AG, DFB Technology, Ltd., Unilever PLC, LANOLIPS PTY LTD and Lanolin Beauty International among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global lamellar ichthyosis treatment market. During the pandemic, the ongoing clinical trials and research activities are temporarily disrupted due to the redirected focus on the COVID-19 pandemic and its related restrictions. Many research institutions and pharmaceutical companies faced challenges in conducting trials, enrolling participants, and ensuring the continuity of research activities. This could have delayed the development of new treatments for lamellar ichthyosis. The pandemic also disrupted the supply chain of these treatment medicines globally.

Why Purchase the Report?

• To visualize the global lamellar ichthyosis treatment market segmentation based on treatment type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of lamellar ichthyosis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global lamellar ichthyosis treatment market report would provide approximately 61 tables, 61 figures, and 187 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Treatment Type
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Adoption of Topical Medications
  • 4.1.2. Restraints
    • 4.1.2.1. Adverse Effects Associated with the Creams
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Pipeline Analysis
• 5.6. Unmet Needs
• 5.7. Volume Analysis
• 5.8. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.1.2. Market Attractiveness Index, By Treatment Type
• 7.2. Moisturizing Creams*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Petrolatum Creams
  • 7.2.4. Lanolin Creams
• 7.3. Emollients
• 7.4. Keratolytic (Anti-Scaling) Creams
• 7.5. Antibiotics
• 7.6. Retinoids (Synthetic Vitamin A Derivatives Drugs)
• 7.7. Moisturizing Eye Drops
• 7.8. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Topical*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Oral
• 8.4. Others

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. LGM Pharma*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Mylan Inc.
• 12.3. Sebapharma GmbH & Co. KG
• 12.4. Timber Pharmaceuticals LLC
• 12.5. Galderma SA
• 12.6. Beiersdorf AG
• 12.7. DFB Technology, Ltd.
• 12.8. Unilever PLC
• 12.9. LANOLIPS PTY LTD
• 12.10. Lanolin Beauty International

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us